autocrine signaling loops, VEGFR-2 succeeded in grabbing attention as one of the leading targets in cancer treatment. Based on the foregoing and our comprehensive studies regarding pharmacophoric features and activity of sorafenib, novel phenylpyridazinone based VEGFR-2 inhibitors 4, 6a-e, 7a,b, 9a,b, 12a-c, 13a,b, 14a,b, 15a,b, and 17a-d were optimized. An assortment of biological assays was conducted
由于其旁分泌和自分泌信号环路,V
EGFR-2 作为癌症治疗的主要靶点之一成功地引起了人们的关注。基于上述内容以及我们对
索拉非尼的药效特征和活性的综合研究,基于新型苯基
哒嗪酮的 V
EGFR-2
抑制剂4 , 6a-e , 7a,b , 9a,b , 12a-c , 13a,b , 14a,b , 15a 、b和17a-d进行了优化。进行了各种
生物测定来评估合成衍
生物的抗血管生成和细胞凋亡活性。体外V
EGFR-2激酶测定验证了合成衍
生物的抑制活性,相对于参比药物
索拉非尼(IC 50 = 81.8 nM),其IC 50值为49.1至418.0 nM。针对 HU
VEC 的抗增殖活性表明,化合物 2-2-[2-(6-oxo-
3-苯基哒嗪-1( 6H )-yl)乙酰基]
肼基}-N- (
对甲苯基)乙酰胺 ( 12c ) 和 2- [(5-巯基-4-甲基- 4H -
1,2,4-三唑-3-基)甲基]-6-苯基
哒嗪-3(